Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen.

Infusional 5-fluorouracil (F) with cisplatin (C) and epirubicin (E), so-called infusional ECF, is a highly active new schedule against locally advanced or metastatic breast cancer. Cisplatin, however, is a major contributor to toxicity and usually requires inpatient treatment. In an attempt to overc...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonnefoi, H., Smith, I. E., O'Brien, M. E., Seymour, M. T., Powles, T. J., Allum, W. H., Ebbs, S., Baum, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074421/
https://www.ncbi.nlm.nih.gov/pubmed/8562348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074421/
https://www.ncbi.nlm.nih.gov/pubmed/8562348

Ejemplares similares